Topical Anesthesia Offers Sufficient Pain Control for MicroPulse Transscleral Laser Therapy for Glaucoma
Table 1
Demographics.
All (n = 8)
Topical plus (n = 4)
Analgosedation (n = 4)
value
Diagnosis
0.486
POAG
4
3
1
PEXG
4
1
3
Gender
0.429
Male
2
2
0
Female
6
2
4
Eye
0.143
RE
3
0
3
LE
5
4
1
Age at treatment (years)
78.3 ± 6.4
73.0 ± 4.3
83.6 ± 1.3
0.221
BCVA at screening (logMAR)
0.3 ± 0.3
0.1 ± 0.1
0.4 ± 0.4
0.103
IOP at screening (mmHg)
17.1 ± 2.7
17.5 ± 3.3
16.8 ± 2.4
0.490
Meds at screening (n)
2.6 ± 1.3
2.8 ± 1.9
2.5 ± 0.6
0.140
Spherical equivalent (D)
0.25 ± 1.78
0.56 ± 1.83
−0.06 ± 1.94
0.903
Mean defect at screening (dB)
5.5 ± 3.6
3.8 ± 3.5
7.2 ± 3.2
0.716
Pain scale at screening (0, …, 10)
0.3 ± 0.8
0.5 ± 1.0
0.0 ± 0.0
0.024
NEI-VFQ at screening (45, …, 256)
119.6 ± 11.8
118.3 ± 11.0
121.0 ± 14.1
0.257
(POAG = primary open-angle glaucoma, PEXG = pseudoexfoliative glaucoma, RE = right eye, LE = left eye, BCVA = best corrected visual acuity, LogMAR = logarithm of the minimum angle Of resolution, mmHg = millimeter of mercury, D = diopter, dB = decibel, and NEI-VFQ = National Eye Institute Visual Function Questionnaire).
